Bamlanivimab improves hospitalization and mortality rates in patients with COVID-19: A systematic review and meta-analysis. Issue 2 (February 2022)

• Record Type: Journal Article
• Authors: Zuo, Ling; Ao, Guangyu; Wang, Yushu; Gao, Ming; Qi, Xin
• Is Part Of: Journal of infection. Volume 84:Issue 2(2022)
• Page Start: 248
• Page End: 288
• Publication Date: 2022-02
• Subjects: COVID-19 -- Bamlanivimab -- Mortality -- SARS-Cov-2; Infection -- Periodicals; Bacterial Infections -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.905
• DOI: 10.1016/j.jinf.2021.09.003
• Languages: English
• ISSNs: 0163-4453

Abstract

Highlights: All studies compared Bamlanivimab monotherapy vs. control group. A total of 8 studies comprising of 13, 573 adult patients with COVID-19 were included. Outcomes suggested Bamlanivimab improved hospitalization and mortality rates.